- Recommendation ID
- NG215/07
- Question
Converting to a medicine with a different half‑life to aid withdrawal: What is the clinical and cost effectiveness of converting to medicines with a longer half‑life to aid withdrawal from benzodiazepines or antidepressants?
- Any explanatory notes
(if applicable) For a short explanation of why the committee made the recommendation for research, see the rationale section on withdrawing a dependence-forming medicine or antidepressant.
Full details of the evidence and the committee's discussion are in evidence review C: safe withdrawal.
Source guidance details
- Comes from guidance
- Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults
- Number
- NG215
- Date issued
- April 2022
Other details
| Is this a recommendation for the use of a technology only in the context of research? | No |
| Is it a recommendation that suggests collection of data or the establishment of a register? | No |
| Last Reviewed | 30/04/2022 |